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Previous studies have reported inconsistent results regarding the modifying effect of hormone replacement therapy (HRT) on the
association of body mass index (BMI) and the risk of colorectal cancer (CRC) among postmenopausal women. We assessed the use
of HRT and BMI in 208 postmenopausal women with histologically confirmed incident CRC and 246 controls in a population-based
case–control study in Germany (DACHS study). Ever use of HRT was strongly associated with reduction of CRC risk (adjusted odds
ratio 0.41, 95% confidence interval 0.25–0.67). Among nonusers of HRT, risk of CRC was strongly increased in women with BMI 27
to o30kgm
 2 (2.76, 1.07–7.12) and obese women (3.30, 1.25–8.72), when compared with women with BMI o23kgm
 2 (P for
trend o0.01). BMI was not associated with risk of CRC among HRT users (P for interaction o0.01). In contrast to most other
studies, a positive association of BMI and CRC risk was found among nonusers of HRT, but not among users of HRT. The reasons for
the inconsistency of results regarding the potential risk modifying effect of postmenopausal hormones in the association of BMI with
CRC remain inconclusive and require further study.
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Hormone replacement therapy (HRT) has been associated with
risk reduction of colorectal cancer (CRC) in the Women’s Health
Initiative (WHI) Estrogen plus Progestin Study and a number of
observational studies (Grodstein et al, 1999; Nanda et al, 1999;
Chlebowski et al, 2004), while body mass index (BMI) X25kgm
 2
was rather consistently associated with an increase of CRC risk in
men and, less consistently and less pronounced, in women (Calle
and Kaaks, 2004). Few studies have previously reported on the
modifying effect of HRT on the association of BMI and CRC risk
among postmenopausal women, and provided conflicting results
(Table 1) (Slattery et al, 2003; Lin et al, 2004; Hou et al, 2006;
Pischon et al, 2006; Adams et al, 2007; Wang et al, 2007). Thus, we
investigated the association of postmenopausal hormone therapy
and BMI with CRC risk in a large population-based study from
Germany.
MATERIALS AND METHODS
Study design and study population
This investigation was conducted within the DACHS study, a
population-based case–control study in the Rhine–Neckar–
Odenwald region in Germany, which was primarily designed to
assess the potential of endoscopic screening for the prevention of
CRC. Details of the study design have been reported elsewhere
(Brenner et al, 2006, 2007a, b; Hoffmeister et al, 2007). Briefly,
patients were included if invasive, and histologically confirmed
CRC (ICD 10 pos. C18–C20) was diagnosed for the first time
between January 2003 and June 2004. All 22 hospitals in the study
region treating patients with CRC agreed to participate in the
study. Control individuals were randomly selected from lists of
population registries and frequency-matched by sex, 5-year age
groups, and county of residence. Cases and controls were included
if they were at least 30 years of age (no upper age limit), German
speaking, and mentally and physically able to participate in a
personal interview of about one hour. Control individuals with a
history of CRC were excluded. If patients complied with the
inclusion criteria, they were informed about the study by their
treating physicians, mostly during hospital stay a few days after
surgery. They were notified to the study centre upon receipt of
informed consent. Controls were contacted by the study centre
through mail and follow-up calls to ask for participation. All
participants gave written informed consent. The study was
approved by the Ethics Committees of the University of Heidelberg
and the State Medical Boards of Baden–Wuerttemberg and
Rhineland–Palatinate.
Exposure assessment
Information on sociodemographic factors and a detailed medical
and lifestyle history with regard to known or suspected protective
factors or risk factors of CRC were collected by trained
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sinterviewers using a questionnaire. Risk factor information was
collected for the time prior and up to the index date, which was the
date of diagnosis for cases and the date of the interview for
controls. In women, use of hormones was ascertained with regard
to treatment of menopausal symptoms or for the prevention of
diseases. Assessment of hormone use included reason, age at
beginning and end of use (or current use), and total duration of
use, but we had no information about the hormone preparations
used. Only HRT use prior to diagnosis (cases) or interview
(controls) was considered. We asked for current weight and
previous weight at each decade of life (i.e., a person of 84 years was
asked about current weight and weight at ages 80, 70, [y], 20). To
calculate BMI, we used the last available weight at least 5 years
prior to the interview (range: 5–14 years, for a person of age 84
this would be weight at age 70). This measure of body weight was
preferred over current BMI, because cancer-related symptoms
before and after diagnosis, or therapy of CRC, might have caused
weight changes.
Menopausal state at index date was defined by reported history
of the women. Postmenopausal women were those whose
menstrual bleedings had stopped naturally or after bilateral
oophorectomy, radiation therapy, or chemotherapy, and all
women older than age 55. However, menopausal state can be
masked if hysterectomy was the reason for the cessation of the
menstrual cycle, or if HRT was started before natural menopause
(Beral, 2003). Thus, women p55 years whose menstrual bleedings
had stopped and, in addition, used HRT for the treatment of
menopausal symptoms (a) in the past or (b) currently for more
than 4 years (duration of perimenopause for most women (Dudley
et al, 1998)) were also defined postmenopausal.
Statistical analysis
We first compared the distribution of potential risk factors and
protective factors among female postmenopausal cases and
controls. Unconditional multiple logistic regression was employed
to estimate odds ratios (ORs) for the association of HRT use and
BMI with CRC risk. We included known or suspected risk factors
or protective factors known from the literature and covariates with
a significantly different distribution between cases and controls
into the model. Then, a backward variable selection procedure was
employed to eliminate all covariates that changed the OR of the
Table 1 Previous studies reporting on the role of HRT in the association of BMI and risk of CRC among postmenopausal women
Relative risk (95% CI) among
postmenopausal women
First author,
year Study design and population Assessment
BMI
(kgm
 2) HRT use No HRT use
Statistical
interaction
Slattery et al Case–control study (USA), 734 HRT use within last 2 years, usual adult o23 1.00 1.00 Po0.01
(2003) postmenopausal colon cancer cases height and weight prior to diagnosis, 23–24 2.69 (1.34–5.40) 1.10 (0.73–1.66)
and 906 controls colon cancer incidence 25–27 1.68 (0.83–3.38) 1.13 (0.79–1.62)
28–30 2.28 (1.07–4.87) 1.01 (0.68–1.51)
430 3.36 (1.58–7.13) 0.98 (0.67–1.44)
Lin et al (2004) Cohort study (USA), 37671 women BMI and HRT use at baseline, CRC o23 1.00 1.00 P¼0.33
(54% postmenopausal), 8.7 years incidence 23.0–24.9 0.81 (0.36–1.84) 2.00 (0.98–4.10)
follow-up, 155 postmenopausal women 25.0–26.9 1.08 (0.47–2.44) 1.32 (0.58–3.02)
with CRC 27.0–29.9 1.98 (0.98–3.99) 1.05 (0.42–2.65)
X30 1.41 (0.65–3.06) 2.91 (1.40–6.06)
Pischon et al Cohort study (Europe), 368277 BMI and HRT use at baseline, colon o21.7 1.00 1.00 Not reported
(2006) women and men, 6.1 years follow-up, cancer incidence 21.7–23.5 0.69 (0.35–1.35) 0.96 (0.63–1.45)
424 postmenopausal women with 23.6–25.7 0.80 (0.41–1.56) 1.21 (0.82–1.78)
colon cancer 25.8–28.8 1.10 (0.57–2.10) 1.11 (0.75–1.64)
X28.9 0.72 (0.31–1.70) 1.12 (0.75–1.67)
Hou et al Case–control study (China), 317 Usual adult weight and height, p19.0 — 1.00 Not applicable
(2006) postmenopausal colon cancer cases population with very rare HRT use 19.1–20.5 — 1.1 (0.6–1.5)
and 534 controls (1%), colon cancer incidence 20.6–21.9 — 0.8 (0.5–1.2)
22.0–23.6 — 0.8 (0.6–1.4)
423.6 — 0.6 (0.3–0.9)
Adams et al Cohort study (USA), 517144 women BMI and HRT use at baseline 18.5 to o23 1.00 1.00 P¼0.28
(2007) and men, B5 years follow-up, 758 (age 50–71), colon cancer incidence 23 to o25 1.07 (0.70–1.63) 1.41 (1.04–1.92)
postmenopausal women with CRC 25 to o27.5 1.56 (1.06–2.29) 1.29 (0.96–1.75)
27.5 to o30 1.52 (0.96–2.40) 1.26 (0.90–1.77)
30 to o35 1.69 (1.09–2.64) 1.05 (0.75–1.48)
X35 1.55 (0.85–2.84) 1.38 (0.96–1.99)
Wang et al Cohort study (USA), 97787 women, BMI 10 years before baseline, HRT Former use
(2007) B10 years follow-up, 814 assessed three times during follow-up, 18.5–24.9 1.00 1.00
postmenopausal women with CRC CRC incidence 25.0–29.9 1.13 (0.85–1.52) 1.08 (0.85–1.37)
X30 0.92 (0.61–1.39) 1.36 (1.04–1.79)
Current use
18.5–24.9 1.00 P¼0.5
25.0–29.9 1.09 (0.80–1.47)
X30 1.14 (0.74–1.75)
BMI¼body mass index; CI¼confidence interval; CRC¼colorectal cancer; HRT¼hormone replacement therapy.
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sexposure under investigation by 3% or less. In the final model, ORs
were adjusted for the matching factors age (per year), county of
residence, and other known or potential confounders: former
colorectal endoscopy (yes/no), BMI (kgm
 2), diagnosis of
rheumatic disease (yes/no), diagnosis of hyperlipidaemia (yes/no,
unknown), former participation in a general health screening
examination (ever/never), ever regular use of nonsteroidal anti-
inflammatory drugs (NSAIDs) including all aspirin use (at least
two times per week for at least 1 year, yes/no), current regular use
of statins (at least two times per week for at least 1 year, yes/no),
average lifetime alcohol consumption (no use and tertiles among
users in grams ethanol per day), oral contraceptive use (o3 years/
X3 years), and lifetime pack-years of active smoking. Other
potential confounders like first-degree family history of CRC,
educational level, number of pregnancies longer than 6 months,
induced menopause (bilateral oophorectomy, radiation therapy, or
chemotherapy), lifetime physical activity, or frequent intake of red
meat, fruits, and vegetables did not materially influence the
estimates, and were not included in the model. Differences between
cases and controls were evaluated using w
2-test, and multivariate
analyses of linear trend were performed for duration of HRT use
and along BMI categories. We tested for effect modification by
introducing a multiplicative interaction term into the models. All
analyses were carried out with the statistical software package SAS
9.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Overall, 540 patients and 614 control persons participated in the
study (43% women). The patients recruited constitute about 50%
of all eligible cases in the study region for the period of
recruitment. Half of the interviews with cases were completed
within 2 weeks after diagnosis, 75% within 1 month, and 88%
within 6 months. Of all potentially eligible controls, 44% agreed to
participate in the interview (another 25% provided less extensive
information in a short questionnaire). Of the 492 women in the
study, 34 pre- or perimenopausal women, and 4 women who
provided no information about HRT use were excluded. The
analysis was restricted to the remaining 208 patients and 246
controls.
The mean age of cases and controls was 69 and 70 years,
respectively. Women with CRC had colon cancer in 68% and
rectum cancer in 32% of cases (of which 5% were in the
rectosigmoid), and tumour stages from I to IV were diagnosed
in 15, 37, 28, and 20% of patients, respectively. The studied CRC
patients and control subjects without CRC were not different
regarding age, educational level, number of pregnancies for more
than 6 months, removal of ovaries and uterus, unnatural induction
of menopause by bilateral oophorectomy, chemotherapy, or
radiation therapy, first-degree family history of CRC, alcohol
consumption, or physical activity. Controls were more likely to
have used oral contraceptives for at least 3 years, to use statins
regularly, and to have smoked less than 30 pack-years of cigarettes.
A statistically significant difference between cases and controls was
found for BMI, former colorectal endoscopy, regular use of
NSAIDs, and for a previous health check-up only (except for BMI,
all more often controls, see Table 2).
Overall, HRT use was associated with strong reduction of CRC
risk in postmenopausal women (OR 0.41, 0.25–0.67), mainly
Table 2 Characteristics of the study population
Cases
N¼208
Controls
N¼246 v
2-test
Age at index year (years)
40–49 2 (1%) 1 (o1%)
50–59 24 (12%) 34 (14%)
60–69 73 (35%) 101 (41%)
70–79 67 (32%) 80 (33%)
80+ 42 (20%) 30 (12%) P¼0.16
BMI (kgm
 2)
a
o23.0 51 (25%) 73 (30%)
23 to o25 39 (19%) 48 (20%)
25 to o27 25 (12%) 49 (20%)
27 to o29 46 (23%) 36 (15%)
30+ 40 (20%) 38 (16%) P¼0.04
Educational level
Low 153 (74%) 181 (74%)
Intermediate 36 (17%) 41 (17%)
High 19 (9%) 21 (10%) P¼0.96
Pregnancies 46 months
0 34 (16%) 32 (13%)
1 58 (28%) 55 (22%)
2 69 (33%) 99 (40%)
3+ 47 (23%) 60 (24%) P¼0.27
Oral contraceptive use
b
o3 years 146 (72%) 157 (64%)
X3 years 58 (28%) 87 (36%) P¼0.10
Bilateral oophorectomy 26 (12%) 27 (11%) P¼0.61
Hysterectomy
c 69 (33%) 89 (36%) P¼0.53
Induced menopause 14 (7%) 16 (6%) P¼0.92
First-degree family history of CRC
d 31 (15%) 34 (14%) P¼0.71
Former colorectal endoscopy
e 42 (20%) 116 (47%) Po0.01
Regular use of NSAIDs
f 57 (27%) 101 (41%) Po0.01
Regular use of statins
g 16 (8%) 32 (13%) P¼0.06
Former health check-up
h 148 (72%) 212 (87%) Po0.01
Active smoking (lifetime pack-years)
i
Never active 140 (67%) 168 (69%)
o10 26 (12%) 37 (15%)
10–19 15 (7%) 19 (8%)
20–29 9 (4%) 14 (6%)
30+ 18 (9%) 7 (3%) P¼0.10
Alcohol, nonuser, and tertiles among users (average lifetime ethanol, gday
 1)
j
0 74 (36%) 71 (29%)
0.1–4.1 44 (21%) 59 (24%)
4.1–9.3 43 (21%) 60 (24%)
49.3 46 (22%) 56 (23%) P¼0.44
Table 2 (Continued)
Cases
N¼208
Controls
N¼246 v
2-test
Physical activity, quartiles (average lifetime METs, hweek
 1)
k
p150.3 57 (28%) 56 (23%)
150.4–220.4 49 (24%) 63 (26%)
220.4–297.9 48 (24%) 65 (26%)
4297.9 50 (25%) 62 (25%) P¼0.64
BMI¼body mass index; CRC¼colorectal cancer; NSAID¼nonsteroidal anti-
inflammatory drug.
aBMI 5–14 years before interview, data missing for seven cases
and two controls.
bData missing for four cases and two controls.
cData missing for
one case.
dData missing for two cases.
eData missing for one case.
fEver regular use of
NSAIDs including aspirin (2+ times per week for 41 year).
gCurrent use; data
missing for four controls.
hData missing for three cases and one control.
iData missing
for one control.
jData missing for one case.
kData missing for four cases.
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samong current users and past users who had stopped HRT less
than 5 years previously (Table 3). No evidence of interaction was
found with previous colorectal endoscopy (P¼0.52) or previous
health check-up visits (P¼0.18) as potential indicators of general
health behaviour with HRT use. The association was similar for
colon cancer (OR 0.35, 0.20–0.61) and for rectum cancer (0.54,
0.25–1.13). The mean duration of HRT use was 9.7, 14.2, and 6.2
years among ever, current, and past users, respectively. Although
there was a significant trend (Po0.01), reduction of CRC risk did
not appear to be stronger with duration of HRT use. The
association of duration of HRT and reduction of CRC risk was
similar among current and past users of HRT (data not shown).
Risk of CRC was increased in women with BMI 27 to o30 and
30þ kgm
 2, when compared with women with BMI o23kgm
 2.
Among nonusers of HRT, compared to those with BMI
o23kgm
 2, women in higher BMI categories, 23 to o25, 25 to
o27, 27 to o30, and 30þ kgm
 2, were at increasing risk of CRC
(Ptrend o0.01). Odds ratios were statistically significant for BMI
Table 3 Association of HRT use with the risk of CRC
OR (95% CI)
a
Cases Controls Basic model
b Adjusted model
b,c
No HRT use 144 (69%) 104 (42%) 1.00 Ref 1.00 Ref
HRT use ever 64 (31%) 142 (58%) 0.30 (0.19–0.46) 0.41 (0.25–0.67)
Current use 29 (14%) 61 (26%) 0.29 (0.17–0.52) 0.35 (0.19–0.67)
Past use
d 35 (17%) 81 (32%) 0.31 (0.19–0.51) 0.45 (0.25–0.79)
Last use 1–4 years previously 11 (5%) 32 (14%) 0.21 (0.10–0.45) 0.26 (0.11–0.63)
Last use 5–9 years previously 8 (4%) 12 (5%) 0.47 (0.18–1.23) 0.68 (0.24–1.97)
Last use X10 years previously 12 (6%) 26 (11%) 0.34 (0.16–0.71) 0.64 (0.24–1.50)
Duration of HRT use
o5 years 19 (9%) 54 (22%) 0.24 (0.13–0.45) 0.38 (0.19–0.74)
5–9 years 16 (8%) 21 (9%) 0.51 (0.24–1.07) 0.70 (0.31–1.60)
10–19 years 22 (11%) 48 (20%) 0.29 (0.16–0.54) 0.36 (0.18–0.71)
20+ years 7 (3%) 19 (8%) 0.25 (0.10–0.62) 0.34 (0.13–0.92)
P for trend
e Po0.01 Po0.01
BMI¼body mass index; CI¼confidence interval; CRC¼colorectal cancer; HRT¼hormone replacement therapy; NSAID¼nonsteroidal anti-inflammatory drug; OR¼odds
ratio.
aEffects of HRT are implicitly weighted across categories of BMI 5–14 years ago.
bORs adjusted for matching factors only (age and county of residence).
cORs additionally
adjusted for BMI, history of rheumatic disease, hyperlipidaemia, former health check-up, former colorectal endoscopy, pack-years of smoking, alcohol, regular use of NSAIDs,
regular use of statins, and oral contraceptive use.
dYear of last use of HRT missing for 11 cases and 4 controls.
eTest statistic was calculated for the following categories: no use,
o5 years, 5–9 years, 10–19 years, and 20+ years.
Table 4 Association of BMI and risk of CRC among postmenopausal women
OR (95% CI)
BMI, 5–14 years ago (kgm
 2)
a Cases Controls Basic model
b Adjusted model
b,c
All women
d
o23 51 (25%) 73 (30%) 1.00 Ref 1.00 Ref
23 to o25 39 (19%) 48 (20%) 1.19 (0.67–2.11) 0.80 (0.42–1.53)
25 to o27 25 (12%) 49 (20%) 0.72 (0.39–1.34) 0.78 (0.39–1.58)
27 to o30 46 (23%) 36 (15%) 1.80 (1.01–3.20) 1.71 (0.89–3.31)
30+ 40 (20%) 38 (16%) 1.60 (0.89–2.87) 1.82 (0.92–3.62)
P for trend P¼0.05 0.02
Never use of HRT
o23 24 (18%) 27 (26%) 1.00 Ref 1.00 Ref
23 to o25 31 (23%) 25 (24%) 1.45 (0.66–3.17) 1.31 (0.55–3.12)
25 to o27 18 (13%) 18 (17%) 1.18 (0.49–2.84) 1.60 (0.58–4.44)
27 to o30 33 (24%) 16 (16%) 2.19 (0.94–5.09) 2.76 (1.07–7.12)
30+ 31 (23%) 17 (17%) 2.11 (0.91–4.88) 3.30 (1.25–8.72)
P for trend P¼0.05 Po0.01
Ever use of HRT
o23 27 (42%) 46 (33%) 1.00 Ref 1.00 Ref
23 to o25 8 (13%) 23 (16%) 0.57 (0.21–1.55) 0.49 (0.16–1.48)
25 to o27 7 (11%) 31 (22%) 0.38 (0.14–1.01) 0.36 (0.11–1.13)
27 to o30 13 (20%) 20 (14%) 1.37 (0.55–3.41) 1.18 (0.40–3.48)
30+ 9 (14%) 21 (15%) 0.68 (0.25–1.81) 0.89 (0.29–2.75)
P for trend P¼0.75 P¼0.96
BMI¼body mass index; CI¼confidence interval; CRC¼colorectal cancer; HRT¼hormone replacement therapy; NSAID¼nonsteroidal anti-inflammatory drug; OR¼odds
ratio.
aBMI missing for seven cases and two controls.
bORs adjusted for matching factors only (age and county of residence).
cORs additionally adjusted for BMI, history of
rheumatic disease, hyperlipidaemia, former health check-up, former colorectal endoscopy, pack-years of smoking, alcohol, regular use of NSAIDs, regular use of statins, and oral
contraceptive use.
dAdditional adjustment for hormone replacement therapy.
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scategories 27 to o30 and 30þ kgm
 2. However, among women
who ever used HRT, BMI was not associated with CRC risk
(Pinteraction o0.01) (Table 4).
DISCUSSION
In this first large population-based case–control study from
Germany, ever use of HRT was associated with strong and
statistically significant reduction of CRC risk of 59%. However,
only current or past use that ended less than 5 years previously was
significantly associated with reduced risk of CRC. Risk reduction
was already apparent after less than 5 years use (OR 0.38, 0.19–
0.74) and did not seem to increase after 10–19 years or 20 years
and longer. BMI was positively associated with increased risk of
CRC among nonusers of HRT, but not among users of HRT.
Two previous randomised controlled trials (RCTs) on HRT
investigated risk of CRC in postmenopausal women. The WHI was
the first trial to report risk reduction of almost 40% by
combination therapy of oestrogen plus progestin (Rossouw et al,
2002; Chlebowski et al, 2004), but not in women with previous
hysterectomy using unopposed conjugated equine oestrogens
(Anderson et al, 2004). CRC risk was, however, not reduced in
postmenopausal women using oestrogen plus progestin in the
HERS trial (hazard ratio (HR) 0.69, 0.32–1.49; Hulley et al, 2002).
In the meta-analysis by Grodstein et al (1999), four out of five
studies providing information about the duration of HRT use
found that protection was similar for all women currently taking
hormones, regardless of duration (Calle et al, 1995; Folsom et al,
1995; Troisi et al, 1997; Grodstein et al, 1998; Paganini-Hill, 1999).
Their summary relative risk for short-term use (RR 0.61, 0.48–
0.79) was very similar to the relative risk for long-term use (RR
0.67, 0.56–0.79). In the WHI, a lower overall risk of CRC in the
hormone group compared with the placebo group emerged after 4
years of treatment (La Vecchia et al, 2005). In the present study,
risk reduction of long-term use X10 years was comparable to that
o5 years, even though a statistically significant trend towards
stronger risk reduction with longer use was observed.
Previous studies have reported inconsistent results regarding
the modifying effect of HRT on the association of body mass and
risk of CRC among postmenopausal women (Table 1). In a large
case–control study within a North American health maintenance
organisation, Slattery et al (2003) reported that BMI was not
related to CRC among postmenopausal women not using HRT, but
among users of HRT: BMI from 23–30 to 430kgm
 2 was
associated with two- to threefold risk of colon cancer, respectively,
when compared with BMI o23kgm
 2. The mechanism by which
oestrogens enhance the positive association was hypothesised to be
upregulation of insulin growth factors, which leads to an increase
in obesity-induced levels of insulin, and thereby increases CRC
risk (Slattery et al, 2003). Lin et al (2004) analysed postmenopausal
women of the Women’s Health Study (WHS), a large RCT
evaluating primary prevention of cancer and CVD by use of
aspirin and vitamin E. In a cohort with a mean follow-up of 8.7
years, they found a positive association of BMI and CRC risk in
both, current and never users of HRT. In another study within the
large prospective NIH–AARP cohort, BMI was positively asso-
ciated with colon cancer risk after 5 years follow-up among women
aged 50–66 years only, and the association was not modified by
HRT (Adams et al, 2007). On the other hand, in the EPIC study
with a mean follow-up of 6.1 years, there was no association of
BMI and risk of colon cancer among HRT users or nonusers,
respectively (Pischon et al, 2006). One major difference between
the WHS, the NIH–AARP, and the EPIC study compared with the
study by Slattery et al (2003) was that the first three cohort studies
defined current use of HRT at baseline (up to 8, 5, or 6 years prior
to diagnosis), whereas in the latter case–control study, use of HRT
was defined as use within the preceding 2 years. In a lean
population from China with very rare HRT use, postmenopausal
women in the highest BMI quintile (423.6kgm
 2) had signifi-
cantly lower risk of colon cancer than those with BMIo19kgm
 2.
The authors hypothesised that higher levels of endogenous
oestrogens increasing with BMI might outweigh the increased risk
of CRC with higher BMI among women who are nonusers of HRT
(Hou et al, 2006).
Yet another finding was obtained in the present study: among
postmenopausal women who never used hormones, risk of CRC
was increased in women with BMI 27 to o30 and 30þ kgm
 2
two- to threefold that of women with BMI o23kgm
 2. A positive
association of BMI and CRC risk was not found among HRT users
(Po0.01). Recently, another large cohort study from the United
States including 814 incident cases with CRC observed a
statistically significant increase in CRC risk among nonusers of
hormones with BMIX30kgm
 2 (HR 1.36, 1.04–1.79), but not
among users, when compared to women with BMIo25kgm
 2
(Wang et al, 2007). However, despite the size of the study, no
significant effect modification of the BMI–CRC association was
found for never, former, and current use of HRT (P¼0.5). Except
for the WHS and the study by Wang et al (2007), all other previous
studies differentiating between users and nonusers of HRT were
mainly reporting on colon cancer risk (Slattery et al, 2003; Hou
et al, 2006; Pischon et al, 2006; Adams et al, 2007), so we repeated
the analysis after exclusion of patients with rectum cancer (32% of
cases). Despite the limited power, ORs were similar for all BMI
groups and risk of CRC was still significantly increased in the two
highest BMI groups among those with no HRT use. Thus, our
results rather indicate that use of HRT might neutralise the
increase of CRC risk associated with overweight and obesity
observed in previous studies (Bergstro ¨m et al, 2001; Lin et al, 2004;
Frezza et al, 2006). On the other hand, this would not be in line
with the biologic mechanisms proposed by Slattery or Hou
(Slattery et al, 2003; Hou et al, 2006). Furthermore, Pischon et al
(2006) found that waist-to-hip ratio and waist circumference were
positively associated with colon cancer risk among nonusers of
HRT, but not among users of HRT, and suggested that measures of
abdominal adiposity might be more closely linked to hormone
effects than BMI.
The strengths of this study include a detailed assessment of
exposure and covariable data. The DACHS study was conducted in
a population-based setting, and lifetime exposures were assessed
and analysed. In particular, we were able to include BMI in the
years before diagnosis and HRT use up to the occurrence of CRC
or the interview.
The study has also some limitations, which require further
discussion. Despite follow-up by mail and phone, the rate of full
participation among eligible control subjects in this study was
slightly less than 50% in this population-based study requiring
personal interviews, blood samples, access to medical records, and
including cases and controls aged 75 or older who are more
difficult to recruit. Only about 50% of eligible cases could be
recruited. Patients were primarily missed due to work overload of
the physicians in charge of recruitment in the hospitals, which is
unlikely to be a source of selection bias. Only few patients refused
to participate. Because of the very strict confidentiality rules in
Germany, it was not possible to quantify these proportions
precisely, as patients may only be contacted through the doctors
in charge of their treatment. Information was available for self-
reported start, end, total duration, and reason of HRT use from the
interview, but may sometimes not have been adequate due to
problems in recalling exact start or duration. However, previous
validation studies have found that ever use of HRT and duration of
use is well recalled (Goodman et al, 1990; Jain et al, 1999; Banks
et al, 2001), and that recall in the present study is similar among
cases and controls (Hoffmeister et al, 2007). If HRT was currently
used, we only asked about the year of start and not the total
duration of use. Interruption periods of several years and
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HRT. The definition of menopausal state may not always be
precise, because it was based on self-reported information of
several factors. But most women in this study were older than 60
years or provided complete information for the definition of
menopausal state. Body mass index was based on self-reported
weight within 5–14 years prior to the index date and height. In
previous validation studies, reported former weight has been
shown to be accurate, but women were slightly more likely to
underestimate their past weight, particularly those with higher
BMI. However, nondifferential misclassification of BMI would
rather have biased the estimates towards no association (Casey
et al, 1991; Perry et al, 1995).
Women who chose to take postmenopausal hormones might
differ from nonusers in ways that may affect CRC risk (Banks et al,
2002). For instance, many of the women in the present study were
long-term users of HRT, which per se requires compliant
behaviour that is generally associated with a healthier lifestyle
and more physician contacts. However, major indicators of health
behaviour or confounders that are associated with risk of CRC
were ascertained and controlled for in the multivariate analysis,
such as former health check-up visits or former endoscopy of the
large intestine. Furthermore, there was no evidence of interaction
for the effect of HRT use on CRC risk with previous endoscopy of
the large intestine (P¼0.52) or previous health check-up visits
(P¼0.18), respectively. However, the power of the study was
limited to detect statistically significant interaction, and confoun-
ders might still have been measured inappropriately, or yet
unknown confounders could have influenced this case–control
study. Finally, we had no details about the hormone preparations
prescribed. Potential differences in drug prescriptions, type of
therapy and duration of use between Germany and other countries,
particularly the United States, might have contributed to the
inconsistency of results (Greiser, 2003; Lo ¨wel et al, 2003; Seifert-
Klauss and Schumm-Draeger, 2003; Bromley et al, 2004; Hersh
et al, 2004).
In conclusion, this first large population-based study of
postmenopausal HRT and risk of CRC from Germany is
compatible with existing evidence of a strong inverse relationship
that was reported from other countries. Similar to earlier reports,
risk reduction was apparent after less than 5 years of use, and did
not decrease further with longer duration of use. A positive
association of BMI and CRC risk was found among nonusers of
HRT, but not among users of HRT, which raises the question
whether risk reduction of CRC associated with HRT use might
neutralise the increase in risk of CRC associated with increasing
BMI. The reasons for the inconsistency of results regarding the role
of postmenopausal hormones in the association of BMI with CRC
risk remain inconclusive and require further study. In this regard,
abdominal obesity might be more closely related to CRC than
general body mass. Because risks seem to outweigh the benefits of
hormone preparations studied in large RCTs, there seems to be no
role for starting or continuing the prevention of CRC and other
chronic diseases with HRT.
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